- Home
- BW vs FENC Comparison
BW vs FENC Comparison
Compare BW & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BW | FENC |
|---|---|---|
| Founded | 1867 | 1996 |
| Country | United States | United States |
| Employees | N/A | 35 |
| Industry | Building Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 372.4M |
| IPO Year | 2015 | 2010 |
Fundamental Metrics
Financial Performance| Metric | BW | FENC |
|---|---|---|
| Price | $7.33 | $10.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.00 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 4.2M | 243.7K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.46 | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | ★ $1,062,388,000.00 | $44,642,000.00 |
| Revenue This Year | $41.58 | $65.12 |
| Revenue Next Year | $66.70 | $41.08 |
| P/E Ratio | ★ N/A | $179.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.64 | $5.65 |
| 52 Week High | $22.03 | $13.25 |
Technical Indicators
Market Signals| Indicator | BW | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 42.58 | 41.25 |
| Support Level | $6.75 | $9.74 |
| Resistance Level | $8.05 | $11.28 |
| Average True Range (ATR) | 0.46 | 0.51 |
| MACD | 0.10 | -0.21 |
| Stochastic Oscillator | 36.00 | 20.53 |
Price Performance
Historical ComparisonAbout BW Babcock & Wilcox Enterprises Inc.
Babcock & Wilcox Enterprises Inc is an energy technologies provider offering energy and emissions control solutions to a broad range of industrial, electrical utility, municipal, and other customers. It offers technologies that utilize coal, natural gas, hydrogen, waste, and biomass to produce energy, environmental solutions, and carbon capture systems. The company's product portfolio comprises steam generation systems, environmental solutions, combustion and fuel systems, and related equipment and services. Additionally, it offers specialized technologies (BrightLoop) in industrial energy production, including hydrogen and syngas. Geographically, the company generates maximum revenue from the United States, and the rest from Canada, the UK, Indonesia, the Philippines, and other markets.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.